Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01651832
Other study ID # 01GY1143
Secondary ID
Status Completed
Phase N/A
First received July 25, 2012
Last updated October 24, 2016
Start date July 2012
Est. completion date December 2015

Study information

Verified date October 2016
Source Martin-Luther-Universität Halle-Wittenberg
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Ministry of Education and Research
Study type Interventional

Clinical Trial Summary

Aim of the study is to increase the proportion of indicated patients with colorectal cancer undergoing adjuvant chemotherapy following surgical resection through an optimized symptom management and logistical support.


Description:

Patients with colorectal cancer in Germany today are exposed to several Problems related to care continuity and access to health care professionals. In order to increase the utilization of adjuvant therapies, patients in the intervention group are offered an additional nursing intervention in the period between discharge after inpatient treatment and the beginning of adjuvant therapy. This includes a telephone follow-up conducted according to guidelines serving to disclose patients' current supportive needs in order to determine potential intervention approaches as early as possible. Hence, the intervention aims to motivate patients not to discontinue the treatment. An early detection of therapy-related physical and psychological impairments aims at optimizing treatment management.

Patients in the intervention group therefore are visited by nursing staff specialized in cancer care (Supportive Cancer Care Networkers, SCAN) during their in-patient stay and are informed about the intervention. An assignment for the SCAN is to support patients in getting access to health care services (e.g. specialists). Patients are given certain information, as for example contact to specialists, voluntary services and the next steps and appointments of the treatment plan are discussed. Within a consultation at the day before hospital discharge, the SCAN takes up the contact information and appoints weekly telephone consultations for the time up to the adjuvant therapy. The SCAN hands out information materials and explains the study documents, as for example patient-held records (PHR) in order to improve therapy compliance.


Recruitment information / eligibility

Status Completed
Enrollment 261
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- colorectal carcinoma (ICD-10: C18, C19, C20)

- indication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed

- living in Saxony-Anhalt

- ECOG-Performance Status <3

- prospective further life expectancy of more than three months

Exclusion Criteria:

- unable to read or understand German properly

- any contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
SCAN
The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.

Locations

Country Name City State
Germany AMEOS Klinikum Aschersleben-Staßfurt GmbH Aschersleben Saxony-Anhalt
Germany Diakonissenkrankenhaus Dessau gGmbH Dessau Saxony-Anhalt
Germany University Hospital Halle Halle Saxony-Anhalt
Germany Diakonissen-Krankhenhaus Leipzig Leipzig Saxony
Germany HELIOS Klinik Lutherstadt Eisleben Lutherstadt Eisleben Saxony-Anhalt
Germany Klinikum Magdeburg gGmbH Magdeburg Saxony-Anhalt
Germany Carl-von-Basedow-Klinikum Merseburg Merseburg Saxony-Anhat
Germany HELIOS Klinik Sangerhausen Sangerhausen Saxony-Anhalt
Germany AMEOS Klinikum Schönebeck GmbH Schönebeck Saxony-Anhalt

Sponsors (1)

Lead Sponsor Collaborator
Martin-Luther-Universität Halle-Wittenberg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of eligible patients undergoing adjuvant chemo therapy 8 weeks after hospital discharge/ chrirurgical resection No
Secondary disease-free survival 8 month after hospital discharge/ chrirurgical resection Yes
Secondary Health-related Quality of Life using the EORTC QLQ-C30 & CR-29 8 weeks & 8 month after hospital discharge/ chrirurgical resection No
Secondary symptom burden using the M.D. Anderson Symptom inventory 8 weeks & 8 month after hospital discharge/ chrirurgical resection No
Secondary Distress using the Distress-Thermometer 8 weeks & 8 month after hospital discharge/ chrirurgical resection No
Secondary supportive care needs using the Supportive Needs Questionnaire-37 (FU-T) 8 weeks & 8 month after hospital discharge/ chrirurgical resection No
Secondary Quality of inpatient care using the EORTC INPATSAT-32 at Baseline No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A